A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.
| Condition(s) | Advanced or Metastatic Non-small Cell Lung Cancer |
|---|---|
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Study type | Interventional |
| Summary | The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC. |
| Who can participate | Inclusion Criteria: * Participants with confirmed squamous or non-squamous NSCLC with a current Stage IV mNSCLC. * Provision of acceptable archival tumour tissue (or fresh tumour tissue biopsy if archival tumour tissue is not available and if clinically feasible) is mandatory at screening. * Measurable disease as defined by at least one lesion that can be accurately measured at baseline as ≥ 10 mm at the longest diameter. * Minimum life expectancy of 12 weeks in the opinion of the investigator. * Adequate organ and marrow function. * Contraceptive use by male or female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * Adequate organ and marrow function. Inclusion Criteria for Sub Study 2: * Program |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | AstraZeneca |
| Locations | Phoenix, Arizona, United States; Santa Rosa, California, United States; Jacksonville, Florida, United States; Baltimore, Maryland, United States; Detroit, Michigan, United States; Rochester, Minnesota, United States (+98 more sites) |
| Start date | 2025-11-24 |
| NCT ID | NCT06996782 |
| Official listing | https://clinicaltrials.gov/study/NCT06996782 |